Primary Antimicrobial Resistance among Mycobacterium Tuberculosis Isolates from HIV Seropositive and HIV Seronegative Patients in Dar es Salaam Tanzania

DSpace/Manakin Repository

Primary Antimicrobial Resistance among Mycobacterium Tuberculosis Isolates from HIV Seropositive and HIV Seronegative Patients in Dar es Salaam Tanzania

Citable link to this page

 

 
Title: Primary Antimicrobial Resistance among Mycobacterium Tuberculosis Isolates from HIV Seropositive and HIV Seronegative Patients in Dar es Salaam Tanzania
Author: Urassa, Willy; Mugusi, Ferdinand; Msamanga, Gernard; Moshiro, Candida; Saathoff, Elmar; Villamor, Eduardo; Bosch, Ronald J.; Fawzi, Wafaie W.

Note: Order does not necessarily reflect citation order of authors.

Citation: Urassa, Willy, Ferdinand Mugusi, Eduardo Villamor, Gernard Msamanga, Candida Moshiro, Ronald Bosch, Elmar Saathoff, and Wafaie Fawzi. 2008. Primary antimicrobial resistance among Mycobacterium tuberculosis isolates from HIV seropositive and HIV seronegative patients in Dar es Salaam Tanzania. BMC Research Notes 1:58.
Full Text & Related Files:
Abstract: Background: The United Republic of Tanzania is one of the 22 high M. tuberculosis burden countries. Data collected between 2002 and 2007 indicate that the global prevalence of drug-resistant M. tuberculosis including MDR vary greatly. The varied drug-resistance patterns make continuous surveillance of drug resistance an essential component of tuberculosis control program. Findings: M. tuberculosis isolates were obtained from consenting adult tuberculosis patients involved in a placebo-controlled study to evaluate the efficacy of multivitamin supplements on response to anti-Tb treatment in Dar es Salaam, Tanzania. Antimicrobial susceptibility testing was done on four antimicrobial agents namely streptomycin, isoniazid, ethambutol and rifampicin. HIV testing and CD4+ T lymphocytes enumeration were also done. A total of 280 M. tuberculosis isolates from 191 (68%) males and 89 (32%) female patients with no previous history of anti-tuberculosis treatment exceeding 4 weeks in the previous 12 months were tested. Among these, 133 (47%) patients were HIV seropositive. Fourteen (5.0%) isolates were resistant to any of the anti-tuberculosis drugs. The prevalence of primary resistance was 5.0%, 0.7%, 0.4% and 0% for isoniazid, streptomycin, rifampicin and ethambutol respectively. One isolate (0.4%) was MDR, with resistance to isoniazid, streptomycin and rifampicin. Conclusion: M. Tb primary resistance rate in a selected population in Dar es Salaam Tanzania is low and efforts should be undertaken to support the Tuberculosis program.
Published Version: doi:10.1186/1756-0500-1-58
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2525641/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:4584790
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters